Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Yang, Soo Jin ^a   Choi, Jung Mook ^b   Chang, Eugene ^b   Park, Sung Woo ^b   Park, Cheol Young ^b  

^a Chonnam National University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ENZYME; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; PROTEIN KINASE LKB1; RNA; ROSIGLITAZONE; SIRTUIN 1; SIRTUIN 1 DEACETYLASE; SIRTUIN 6; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; SIRTUIN; SIRTUIN 6, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FATTY LIVER; GENE EXPRESSION; IN VIVO STUDY; LIPID STORAGE; LIVER CELL; MALE; MOUSE; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL LINE; DRUG EFFECTS; GENE SILENCING; GENETICS; LIPID METABOLISM; LIVER; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; FATTY LIVER; GENE KNOCKDOWN TECHNIQUES; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIVER; MALE; MICE; RATS; SIGNAL TRANSDUCTION; SIRTUIN 1; SIRTUINS; THIAZOLIDINEDIONES;

EID: 84940236618     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105456     Document Type: Article

References (37)

1. Schug TT, Li X (2011) Sirtuin 1 in lipid metabolism and obesity. Ann Med 43: 198-211.
2. Xiao C, Kim HS, Lahusen T, Wang RH, Xu X, et al. (2010) SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J Biol Chem 285: 36776-36784.
3. Zhong L, Mostoslavsky R (2010) SIRT6: a master epigenetic gatekeeper of glucose metabolism. Transcription 1: 17-21.
4. Kitada M, Koya D (2013) SIRT1 in Type 2 Diabetes: Mechanisms and Therapeutic Potential. Diabetes Metab J 37: 315-325.
5. Haigis MC, Guarente LP (2006) Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 20: 2913-2921. (Pubitemid 44771725)
6. Haigis MC, Sinclair DA (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5: 253-295.
7. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, et al. (2007) SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 6: 759-767. (Pubitemid 350131044)
8. Banks AS, Kon N, Knight C, Matsumoto M, Gutierrez-Juarez R, et al. (2008) SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8: 333-341.
9. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH (2008) Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 105: 9793-9798. (Pubitemid 352031379)
10. Xu F, Gao Z, Zhang J, Rivera CA, Yin J, et al. (2010) Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: a role of lipid mobilization and inflammation. Endocrinology 151: 2504-2514.
11. Li Y, Wong K, Giles A, Jiang J, Lee JW, et al. (2014) Hepatic SIRT1 Attenuates Hepatic Steatosis and Controls Energy Balance in Mice by Inducing Fibroblast Growth Factor 21. Gastroenterology 146: 539-549.
12. Kanfi Y, Peshti V, Gil R, Naiman S, Nahum L, et al. (2010) SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell 9: 162-173.
13. Kim HS, Xiao C, Wang RH, Lahusen T, Xu X, et al. (2010) Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab 12: 224-236.
14. Canto C, Auwerx J (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20: 98-105.
15. Lan F, Cacicedo JM, Ruderman N, Ido Y (2008) SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 283: 27628-27635.
16. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P (2008) Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 582: 46-53. (Pubitemid 350297246)
17. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, et al. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118. (Pubitemid 40349395)
18. Shen Z, Liang X, Rogers CQ, Rideout D, You M (2010) Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 298: G364-374.
19. Daitoku H, Hatta M, Matsuzaki H, Aratani S, Ohshima T, et al. (2004) Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci U S A 101: 10042-10047. (Pubitemid 38891191)
20. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, et al. (2010) The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140: 280-293.
21. Jing E, Gesta S, Kahn CR (2007) SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab 6: 105-114. (Pubitemid 47163621)
22. Palacios OM, Carmona JJ, Michan S, Chen KY, Manabe Y, et al. (2009) Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (Albany NY) 1: 771-783.
23. Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, et al. (2011) Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J 433: 505-514.
24. Ferre P (2004) The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1: S43-50.
25. Olefsky JM (2000) Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106: 467-472.
26. Lee JW, Nam-Goong IS, Kim JG, Yun CH, Kim SJ, et al. (2010) Effects of rosiglitazone on inflammation in Otsuka long-evans Tokushima Fatty rats. Korean Diabetes J 34: 191-199.
27. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, et al. (2006) Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 291: E175-181. (Pubitemid 44035323)
28. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, et al. (2004) Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314: 580-585. (Pubitemid 38084758)
29. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, et al. (2006) Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26: 624-630.
30. Yang SJ, Choi JM, Chae SW, Kim WJ, Park SE, et al. (2011) Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS One 6: e17057.
31. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, et al. (2003) Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52: 1364-1370. (Pubitemid 36666189)
32. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, et al. (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135: 100-110. (Pubitemid 351916703)
33. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, et al. (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39: 188-196. (Pubitemid 38461481)
34. Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H (2012) Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepat Mon 12: e6099.
35. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, et al. (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283: 20015-20026.
36. Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, et al. (2006) Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 4: 1048-1052. (Pubitemid 44118842)
37. Qiao L, Shao J (2006) SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 281: 39915-39924. (Pubitemid 46041795)